منتجاتنا

Description:

 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.

Composition:

Each film-coated tablet contains Linagliptin INN 5 mg.

Indication:

Linagliptin is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults. As Monotherapy: In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment. As combination therapy: in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. In combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. In combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Dosage & Administration:

• The recommended dose of Linagliptin is 5 mg once daily.
• Linagliptin can be taken with or without food at any time of the day. If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
• For patients with renal insufficiency no dosage adjustment is required
• Pharmacokinetic studies suggest  that no dose adjustment is required for patients with  hepatic impairment
• When Linagliptin is added to Metformin the dose of Metformin should be maintained and Linagliptin administered concomitantly.
• When Linagliptin is used in combination with a sulphonylurea or with Insulin, a lower dose of the Sulphonylurea or Insulin, may be considered to reduce the risk of hypo glycaemia.